Clinical Research Directory
Browse clinical research sites, groups, and studies.
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
Sponsor: Nanfang Hospital, Southern Medical University
Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT. Poor erythroid engraftment is associated with increased bleeding events and shorter survival. Current treatment methods such as epoetin or repeated red-cell transfusions are not effective for poor erythroid engraftment, with limited and transient responses. Retrospective studies suggested that luspatercept showed efficacy in patients with anemia post-transplantation or poor erythroid engraftment. However, there are no studies comparing luspatercept versus epoetin for the treatment of poor erythroid engraftment. Therefore, we conducted a randomized controlled study to compared the effect of luspatercept versus epoetin in treating poor erythroid engraftment for hematological malignancies.
Official title: Luspatercept Versus Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-06-15
Completion Date
2030-12-31
Last Updated
2026-06-09
Healthy Volunteers
No
Interventions
Luspatercept
Luspatercept is administered 1.0mg/kg subcutaneously every 3 weeks; If the hemoglobin level does not increase after two consecutive administrations, the dose will be adjusted to 1.3mg/kg. If the hemoglobin level returns to the normal range, Luspatercept will be given once before discontinuing the medication.
Epoetin
Epoetin is administered 15000 IU subcutaneously every 3 weeks for 24 weeks
Locations (1)
Department of Hematology, Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China